Five years after bottoming out, Bristol Myers Squibb has moved to the first division of pharma companies with three of the world’s top eight drugs in its portfolio.
Gilead’s top line in 2020 got help from an unexpected source – a failed developmental hepatitis C compound that turned out to be effective against COVID-19.
GSK continues to increase investment in the company pipeline, build on top-line momentum for key growth drivers, and largely complete readiness for the consumer healthcare business separation.
J&J has been investing in and applying the best science to take on the most serious public health threats for more than a century, including global efforts to combat COVID-19.
Long known as a diabetes company, most of Lilly’s up-and-coming drugs are concentrated on other diseases and conditions.
New CEO Richard Davis inherits a company for whom oncology was once an afterthought, but now depends on one oncology drug for 30 percent of its revenue.
Novartis took actions that paved the way for future growth as the company increased sales and operating profit, generated good cash flows, and continued to innovate.
In addition to all the efforts in the fight against the COVID-19 pandemic, Roche has continued to develop innovative medicines for other serious diseases.
For Sanofi, investment in mRNA technology, immuno-oncology and corporate social responsibility are all part of the company’s “Play to Win” strategy.
Through the course of the COVID pandemic, the Takeda that company leaders imagined before acquiring Shire has begun to take shape.
